Interpore Cross International
This article was originally published in The Gray Sheet
Firm's Pro Osteon 500 bone graft substitute gains FDA approval for expanded indications in treating cysts and tumors in long bones, both in the metaphysis and the diaphysis. The expanded approval via premarket approval application supplement now allows the firm's domestic sales force, which includes direct reps and agents, to promote Pro Osteon to the orthopedic surgical oncologist, the firm says. The product was approved in October 1992 for use in acute, metaphyseal long bone fractures ("The Gray Sheet" Nov. 9, 1992, I&W-4)...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.